FMP
Infinity Pharmaceuticals, Inc.
INFI
NASDAQ
Inactive Equity
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
0.008 USD
-0.0088 (-110%)
2022
2021
2020
2019
2.59M
1.86M
1.72M
3.05M
1.56M
1.12M
1.04M
7.31M
1.03M
738k
682k
-4.26M
45.87M
45.82M
39.18M
41.41M
32.41M
31.65M
26.76M
27.12M
13.46M
14.17M
12.42M
14.29M
0
0
0
0
13.46M
14.17M
12.42M
14.29M
1.56M
1.12M
1.04M
7.31M
-44.84M
-45.08M
-38.5M
-45.66M
475k
-179k
-2M
-1.45M
-44.37M
-45.26M
-40.49M
-47.11M
-1.11M
180k
2.44M
-54k
-43.26M
-45.44M
-42.94M
-47.06M
-0.48
-0.53
-0.72
-0.83
-0.48
-0.53
-0.72
-0.83
89.25M
85.6M
59.86M
56.98M
89.25M
85.6M
59.86M
56.98M
-44.84M
-44.6M
-38.01M
-45.66M
2022
2021
2020
2019
-811.58M
-766.32M
-725.83M
-678.77M
-43.26M
-45.44M
-42.94M
-47.06M
0
0
0
0
0
0
0
0
-855.95M
-811.58M
-766.32M
-725.83M
-44.37M
-45.26M
-40.49M
-47.06M
2022
2021
2020
2019
800k
2.31M
3.13M
2.19M
458k
480k
483k
219k
-17k
-11k
-43k
-2.33M
359k
1.84M
2.69M
4.29M
2022
2021
2020
2019
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.